Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 6/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.48 |
| ▸ | PPARA | Q07869 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.45 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24805947 | 0.85 | L3MBTL1 (0.54) | L3MBTL1MEN1KMT2APPARGFFAR1 | |
| SCHEMBL355627 | 0.83 | L3MBTL1 (0.67) | L3MBTL1MEN1KMT2APPARGFFAR1 | |
| SCHEMBL21991528 | 0.81 | NR4A2 (0.67) | L3MBTL1FFAR1MAOBFFAR4NR4A2 | |
| SCHEMBL23605894 | 0.80 | PPARG (0.53) | PPARGPPARA | |
| SCHEMBL8582394 | 0.79 | L3MBTL1 (0.61) | L3MBTL1FFAR1FFAR4MMP2 | |
| SCHEMBL5099590 | 0.76 | SLC6A4 (0.54) | PPARGPPARAALOX15 | |
| SCHEMBL21991829 | 0.76 | PPARA (0.62) | L3MBTL1PPARGPPARALMNAMAOB | |
| SCHEMBL21991847 | 0.76 | L3MBTL1 (0.58) | L3MBTL1FFAR1PPARALMNAMAOB | |
| SCHEMBL2180164 | 0.75 | L3MBTL1 (0.57) | L3MBTL1MEN1KMT2AFFAR1LMNA | |
| SCHEMBL120716 | 0.75 | KMT2A (0.58) | L3MBTL1MEN1KMT2AFFAR1PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10940132-B2 | CCL5 inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200138766-A1 | CCL5 INHIBITORS | LAPKO INC. DBA AFECTA PHARMACEUTICALS | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200138766-A1 | CCL5 INHIBITORS | CCL5, CCL11, CCR5 | L3MBTL1 1170/4885MEN1 3749/4885KMT2A 4842/4885 |
| US-10940132-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | L3MBTL1 1170/4885MEN1 3749/4885KMT2A 4842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.